Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”

Ivan Vogelius; Joachim Yahalom; Lena Specht; Richard Hoppe; Tim Illidge

首页> 外文期刊>The oncologist >Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”

【24h】

Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”

机译：评论：“国际系列161例有限期弥漫性大B细胞淋巴瘤的临床特征，治疗和预后（IELSG-14研究）”

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The oncologist》 |2014年第12期|共页
作者
Ivan Vogelius; Joachim Yahalom; Lena Specht; Richard Hoppe; Tim Illidge;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)" [J] . Hoppe Richard, Illidge Tim, Specht Lena, The oncologist . 2014,第12期

机译：评论：“国际系列161例有限期弥漫性大B细胞淋巴瘤的临床特征，治疗和预后（IELSG-14研究）”
2. Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study) Reply [J] . Ferreri Andres J. M., Gospodarowicz Mary, Zucca Emanuele, The oncologist . 2014,第12期

机译：161例有限期弥漫性大型B细胞淋巴瘤的国际临床研究，临床治疗和预后（IELSG-14研究）
3. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) [J] . BrunoVentreM., FerreriA.J.M., GospodarowiczM., The oncologist . 2014,第3期

机译：国际性161例有限期骨弥漫性大B细胞淋巴瘤患者的临床特征，治疗和预后（IELSG-14研究）
4. Clinical significance and expression of microRNA-21 in diffuse large B-cell lymphoma cell lines and serum of patients [C] . CHEN Wei-qun, LU Honf-da, KONG De-yong, 2011 Asia-Pacific Conference of tumor biology and medicine . 2011

机译：患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Comment on: Clinical Features Management and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study) [O] . Richard Hoppe, Tim Illidge, Lena Specht, 2014

机译：评论：国际系列161例有限期弥漫性大B细胞淋巴瘤的临床特征治疗和预后（IELSG-14研究）
7. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). [O] . Bruno Ventre, Marta, Ferreri, Andrés J M, Gospodarowicz, Mary, 2014

机译：国际系列161例骨性弥漫性弥漫性大B细胞淋巴瘤患者的临床特征，治疗和预后（IELsG-14研究）。

Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”

著录项

相似文献

相关主题

期刊订阅